Evidence map›Paper›PMID 39487235›Full record

ArticleGenes and immunity2025

The HLA-B -21 M/T dimorphism associates with disease severity in COVID-19.

Benedikt Strunz, Pouria Momayyezi, Eleni Bilev, Jagadeeswara Rao Muvva, Puran Chen, Jonna Bister, Marie Schaffer, Mira Akber, Martin Cornillet, Karolinska KI/K COVID-19 Study Group and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes and immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Investigation ofInternational journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Benedikt Strunz *Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Pouria Momayyezi *Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Eleni BilevCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Jagadeeswara Rao MuvvaCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Puran ChenCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Jonna BisterCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Marie SchafferCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Mira AkberCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Martin CornilletCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Karolinska KI/K COVID-19 Study Group
Amir HorowitzDepartment of Oncological Sciences, Precision Immunology Institute, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Karl-Johan MalmbergCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Olav RooyackersDivision of Anesthesiology and Intensive Care, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Soo AlemanDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Hans-Gustaf LjunggrenCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Niklas K BjörkströmCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Kristoffer StrålinDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0002-8801-3169
Quirin HammerCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. quirin.hammer@ki.se.ORCID 0000-0003-2968-6061

Funding

Natural Killer cells and the Immunogenetics of COVID-19R01AI158410 · NIAID · UNIVERSITY OF COLORADO DENVER · PI NORMAN, PAUL JOHN · 2021 to 2024
$2.9M
NIAID NIH HHS R01 AI158410
6 · The paper itself

Abstract

Host genetics shape immune responses and influence severity of infectious diseases. The HLA-B -21 M/T dimorphism tunes the functionality of natural killer (NK) cells expressing the inhibitory receptor NKG2A. NKG2A

Indexed as

COVID-19HLA-B AntigensAdultAgedFemaleGenotypeHumansKiller Cells, NaturalMaleMiddle AgedNK Cell Lectin-Like Receptor Subfamily CSARS-CoV-2Severity of Illness IndexHLA-B AntigensNK Cell Lectin-Like Receptor Subfamily C

Identifiers

PMID39487235
PMCPMC11832411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.